

Gerrit Jan Wolbink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8102588/publications.pdf>

Version: 2024-02-01

140
papers

14,435
citations

16411

64
h-index

19136

118
g-index

140
all docs

140
docs citations

140
times ranked

14511
citing authors

#	ARTICLE	IF	CITATIONS
1	Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 129-136.	0.6	8
2	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 65-73.	0.5	24
3	Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 402-405.	0.5	13
4	COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2022, 4, e310-e313.	2.2	12
5	Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	18
6	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2022, 8, e002216.	1.8	10
7	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. <i>Science</i> , 2021, 371, .	6.0	244
8	Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs subcutaneous administration: results of a randomized controlled clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3162-3176.	1.1	11
9	High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	166
10	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. <i>Trials</i> , 2021, 22, 406.	0.7	1
11	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e778-e788.	2.2	130
12	Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e542-e545.	2.2	54
13	Elevated Fab glycosylation of anti-hinge antibodies. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-8.	0.6	3
14	Response to tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study by Marotte et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e82-e82.	0.5	1
15	The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2020, 59, 1703-1708.	0.9	8
16	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology</i> , The, 2020, 2, e583-e585.	2.2	40
17	Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG Targets. <i>Arthritis and Rheumatology</i> , 2020, 72, 2005-2016.	2.9	8
18	Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1417-1425.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Immunogenicity of TNF-Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 312.	2.2	94
20	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2129-2137.	0.3	6
21	Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses. <i>European Journal of Immunology</i> , 2020, 50, 1113-1125.	1.6	18
22	The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 306-313.	0.4	9
23	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
24	Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 837-848.	1.3	71
25	Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 266-270.	0.6	11
26	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
27	Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 66.	1.6	10
28	Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 869-873.	0.9	7
29	Comment on "Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial" by Tanaka et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216557.	0.5	3
30	Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy. <i>Journal of Rheumatology</i> , 2019, 46, 117-118.	1.0	2
31	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 484-487.	0.5	59
32	Response to: Comment on "Ami et al" titled "Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial" by den Broeder et al. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e68-e68.	0.5	0
33	Restricted immune activation and internalisation of anti-idiotypic complexes between drug and antidrug antibodies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1471-1479.	0.5	23
34	Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra [®] micro-sampler vs dried blood spot. <i>Bioanalysis</i> , 2018, 10, 815-823.	0.6	41
35	Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1285-1288.	0.5	14
36	Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2474-2484.	1.1	31

#	ARTICLE	IF	CITATIONS
37	Anti-Hinge Antibodies Recognize IgG Subclassâ€œ and Protease-Restricted Neopeptides. <i>Journal of Immunology</i> , 2017, 198, 82-93.	0.4	25
38	Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1035-1037.e6.	1.5	21
39	Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange. <i>Scientific Reports</i> , 2016, 6, 32747.	1.6	42
40	Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. <i>Oncologist</i> , 2016, 21, 1260-1268.	1.9	87
41	Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. <i>Arthritis Research and Therapy</i> , 2016, 18, 290.	1.6	28
42	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 578-585.	0.5	161
43	Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 120, 198-201.	1.4	20
44	Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e24-e24.	0.5	9
45	Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1170-1176.	0.5	72
46	Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 655-62.	0.4	4
47	IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Antiâ€œCitrullinated Protein Antibodyâ€œ Associated or Isotypeâ€œ Switched IgA Responses. <i>Arthritis and Rheumatology</i> , 2015, 67, 3124-3134.	2.9	33
48	Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. <i>Journal of Immunological Methods</i> , 2015, 418, 29-38.	0.6	70
49	Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24â€œ weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 396-401.	0.5	66
50	A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e15-e15.	0.5	62
51	The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. <i>British Journal of Dermatology</i> , 2015, 173, 855-857.	1.4	35
52	Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. <i>Arthritis Research and Therapy</i> , 2015, 17, 78.	1.6	48
53	Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24â€œ weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1825-1829.	0.5	51
54	Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity. <i>Journal of Rheumatology</i> , 2015, 42, 1638-1646.	1.0	32

#	ARTICLE	IF	CITATIONS
55	Key findings towards optimising adalimumab treatment: the concentrationâ€“effect curve. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 513-518.	0.5	169
56	The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 311-314.	0.5	104
57	Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1915-1923.	0.5	53
58	Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 361-368.	0.5	81
59	The minipig as an alternative non-rodent model for immunogenicity testing using the TNF± blockers adalimumab and infliximab. <i>Journal of Immunotoxicology</i> , 2014, 11, 62-71.	0.9	18
60	Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52â€“weeks of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2178-2182.	0.5	70
61	Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies. <i>Journal of Biological Chemistry</i> , 2014, 289, 34482-34488.	1.6	54
62	Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2217-2219.	0.5	33
63	Antibodies to IgG4 Hinge Can Be Found in Rheumatoid Arthritis Patients During All Stages of Disease and May Exacerbate Chronic Antibodyâ€“Mediated Inflammation. <i>Arthritis and Rheumatology</i> , 2014, 66, 1133-1140.	2.9	31
64	Methotrexate Normalizes Upâ€“Regulated Folate Pathway Genes in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2791-2802.	6.7	46
65	Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF± biologics in rheumatic diseases. <i>Clinical Rheumatology</i> , 2013, 32, 1429-1435.	1.0	89
66	Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. <i>Rheumatology</i> , 2013, 52, 547-553.	0.9	65
67	Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 164-172.	3.5	364
68	Nanomolar to sub-picomolar affinity measurements of antibodyâ€“antigen interactions and protein multimerizations: Fluorescence-assisted high-performance liquid chromatography. <i>Analytical Biochemistry</i> , 2013, 437, 118-122.	1.1	11
69	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
70	Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients. <i>Rheumatology</i> , 2013, 52, 1462-1466.	0.9	3
71	Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. <i>Rheumatology</i> , 2013, 52, 631-635.	0.9	42
72	Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 104-109.	0.5	223

#	ARTICLE	IF	CITATIONS
73	Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 593-600.	1.4	109
74	Long-term measurement of anti-adalimumab using pH-shift-anti-idiotypic antigen binding test shows predictive value and transient antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1680-1686.	0.5	82
75	Immunogenicity of biological therapeutics. <i>Current Opinion in Rheumatology</i> , 2012, 24, 306-311.	2.0	69
76	Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 88-91.	0.5	121
77	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. <i>Arthritis and Rheumatism</i> , 2012, 64, 3850-3855.	6.7	68
78	Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1914-1915.	0.5	196
79	The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia – A Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2012, 39, 1914-1917.	1.0	13
80	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 184.	0.8	25
81	IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients. <i>Journal of Clinical Immunology</i> , 2012, 32, 1000-1006.	2.0	57
82	Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing. <i>Journal of Immunological Methods</i> , 2012, 375, 93-99.	0.6	77
83	The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 284-288.	0.5	149
84	Differential effect of drug interference in immunogenicity assays. <i>Journal of Immunological Methods</i> , 2011, 372, 196-203.	0.6	146
85	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 12.	0.8	35
86	Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study. <i>Arthritis and Rheumatism</i> , 2011, 63, 877-883.	6.7	104
87	Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3226-3233.	6.7	186
88	Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. <i>Analytical Biochemistry</i> , 2011, 411, 271-276.	1.1	60
89	The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 128-133.	0.5	156
90	Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1460.	3.8	656

#	ARTICLE	IF	CITATIONS
91	A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients. <i>Journal of Immunological Methods</i> , 2010, 362, 82-88.	0.6	152
92	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
93	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	9.4	1,132
94	Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 817-821.	0.5	192
95	Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 624-625.	0.5	75
96	Tumour necrosis factor blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1281-1285.	0.5	53
97	Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis. <i>Archives of Dermatology</i> , 2010, 146, 127-32.	1.7	137
98	Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 409-412.	0.5	100
99	Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 490-494.	0.5	232
100	Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. <i>Arthritis Research and Therapy</i> , 2010, 12, R221.	1.6	58
101	The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. <i>Arthritis Research and Therapy</i> , 2010, 12, 217.	1.6	96
102	A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1303-1309.	0.5	84
103	Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1787-1788.	0.5	83
104	Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 531-535.	0.5	121
105	Copy number variation at the <i>FCGR</i> locus includes <i>FCGR3A</i> , <i>FCGR2C</i> and <i>FCGR3B</i> but not <i>FCGR2A</i> and <i>FCGR2B</i> . <i>Human Mutation</i> , 2009, 30, E640-E650.	1.1	141
106	Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1324-1330.	6.7	101
107	Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1484-1490.	6.7	112
108	Genetic variants at <i>CD28</i> , <i>PRDM1</i> and <i>CD2/CD58</i> are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009, 41, 1313-1318.	9.4	306

#	ARTICLE	IF	CITATIONS
109	Dealing with immunogenicity of biologicals: assessment and clinical relevance. <i>Current Opinion in Rheumatology</i> , 2009, 21, 211-215.	2.0	173
110	Immunogenicity of anti-tumor necrosis factor antibodies toward improved methods of anti-antibody measurement. <i>Current Opinion in Immunology</i> , 2008, 20, 431-435.	2.4	177
111	Common variants at CD40 and other loci confer risk of rheumatoid arthritis. <i>Nature Genetics</i> , 2008, 40, 1216-1223.	9.4	476
112	Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1122-1126.	1.9	188
113	The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1139-1144.	0.5	131
114	Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1697-1701.	0.5	46
115	IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 425-8.	1.0	16
116	Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1972-7.	1.0	44
117	Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 921-926.	0.5	492
118	Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1252-1254.	0.5	124
119	Do C-reactive protein levels help predict onset of rheumatoid arthritis in women?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 318-319.	3.2	0
120	Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 958-961.	0.5	91
121	The effects of continuous venovenous hemofiltration on coagulation activation. <i>Critical Care</i> , 2006, 10, R150.	2.5	26
122	Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 711-715.	6.7	438
123	High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1249-1250.	0.5	31
124	Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 133-134.	0.5	46
125	Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 253-256.	0.5	162
126	Detection of soluble human granzyme, Kin vitro and in vivo. <i>European Journal of Immunology</i> , 2005, 35, 2940-2948.	1.6	48

#	ARTICLE	IF	CITATIONS
127	Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. <i>Arthritis and Rheumatism</i> , 2005, 52, 2740-2750.	6.7	462
128	Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 704-707.	0.5	193
129	Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 252-5.	1.0	80
130	Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. <i>Arthritis and Rheumatism</i> , 2003, 48, 2996-2997.	6.7	46
131	Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. <i>Journal of Hepatology</i> , 2000, 32, 783-791.	1.8	42
132	C-Reactive Protein as a Cardiovascular Risk Factor. <i>Circulation</i> , 1999, 100, 96-102.	1.6	790
133	Complement Activation in Patients with Sepsis Is in Part Mediated by C-reactive Protein. <i>Journal of Infectious Diseases</i> , 1998, 177, 81-87.	1.9	77
134	Inhibition of human complement by β_2 -glycyrrhetic acid. <i>Immunology</i> , 1997, 90, 115-120.	2.0	103
135	C-Reactive Protein Colocalizes With Complement in Human Hearts During Acute Myocardial Infarction. <i>Circulation</i> , 1997, 95, 97-103.	1.6	321
136	Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. <i>Journal of Immunological Methods</i> , 1993, 163, 67-76.	0.6	111
137	The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant Interleukin-2. <i>British Journal of Cancer</i> , 1992, 65, 96-101.	2.9	47
138	Effects on leukocytes after injection of tumor necrosis factor into healthy humans. <i>Blood</i> , 1992, 79, 693-698.	0.6	133
139	Interplay of complement and cytokines in the pathogenesis of septic shock. <i>Immunopharmacology</i> , 1992, 24, 135-148.	2.0	52
140	Effects on leukocytes after injection of tumor necrosis factor into healthy humans. <i>Blood</i> , 1992, 79, 693-698.	0.6	1